zopapogene imadenovecsipuleucel-TPD-1 blockerrecurrent respiratory papillomatosisFood and Drug Administrationhormone-resistant metastatic prostate cancerR/M HPV16+ head and neck cancer
…ic prostate cancer and targeting prostate acid phosphatase; and zopapogene imadenovec, approved in 2025 for recurrent respiratory papillomatosis, a r…